5 Key Takeaways

• 1

  Research at the Euretina congress highlights transferrin's potential role in dry AMD progression.

• 2

  PulseSight Therapeutics analyzed a large dataset revealing elevated iron levels in AMD patients.

• 3

  The study suggests that iron dysregulation contributes to oxidative stress and ferroptosis in AMD.

• 4

  Transferrin may protect against ferroptosis by maintaining iron balance in retinal cells.

• 5

  PST-611, a therapy encoding transferrin, is currently in phase 1 clinical trials for dry AMD.